Results of a recent study suggest that immunosuppressive therapy with anti-thymocyte globulin and cyclosporine is associated with improved blood cell counts in patients with low- to intermediate-risk myelodysplastic syndromes.

However, the treatment did not have a significant impact on progression to leukemia and overall survival.

Previous research has suggested that the immune system may be involved in the development of abnormal blood cells, which is the main cause of myelo­dysplastic syndromes (MDS). As a result, researchers have theorized that suppression of the immune system may treat MDS.

Two of the…